• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Del spells relief SEC

Article

The Securities and Exchange Commission has relieved Del Global Technologies from requirements to file selected financial data for fiscal years 1999 and 1998. Consequently, the beleaguered maker of x-ray equipment need file only three years of financial

The Securities and Exchange Commission has relieved Del Global Technologies from requirements to file selected financial data for fiscal years 1999 and 1998. Consequently, the beleaguered maker of x-ray equipment need file only three years of financial data rather than five. Del executives successfully argued that they could not prepare reliable statements of operations for FY 1999 and 1998 due to a turnover in personnel and the absence of records. With this, the company can now file a form S-1 registration statement with the SEC covering the issuance of one million shares underlying the warrants issued by Del as part of a shareholder class action suit. The SEC must review and declare effective the issuance of shares.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.